- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Is Bariatric Surgery at Risk Due to Ozempic? (201-204_Level 2_South; In Person Only) - Aug 9, 2024 - Abstract #ACSCLINCON2024ACS_CLINCON_2317;
The increased use of Ozempic has led to fewer bariatric surgeries, though its long-term effects on patient outcomes and clinical practice warrant further investigation. Descriptive Characteristics Comparing Ozempic vs Non- Ozempic Bariatric Patients Not on Ozempic (N=446) On Ozempic (N=69) Overall (N=515) Caucasian (%) 184 (41.3) 30 (43.5) 214 (41.6) Female Gender (%) 368 (82.5) 52 (75.4) 420 (81.6) Mean Age (SD) 42 (12.1) 45.1 (13.6) 42.4 (12.4) Diabetes (%) 100 (22.4) 31 (44.9) 131 (25.4) Median Starting BMI (IQR) 41.8 (8.8) 42.8 (9.1) 42 (8.8) Median Pre-Op BMI (IQR) 41.4 (8) 41.6 (5.2) 41.4 (8) Median Lowest BMI Pre- OR (IQR) 37.3 (10.2) 39.7 (10) 37.6 (10.2) Surgery (%) 245 (55) 23 (33.3) 268 (52) Didn
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
The Skinny on Ozempic: Approaching GLP-1 Use Perioperatively (Exhibit Hall) - Aug 6, 2024 - Abstract #ASA2024ASA_5853;
Despite taking semaglutide the morning of the surgery, an OG tube placed intraoperatively did not return significant gastric secretions. The intubation and subsequent procedures were uneventful.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Hidden Dangers in Patients taking Semaglutide (Ozempic) (Exhibit Hall) - Aug 6, 2024 - Abstract #ASA2024ASA_4840;
There is also a lack of consensus in perioperative guidelines. Here, we discuss the pharmacokinetics of semaglutide, our medically challenging case involving a patient taking semaglutide, and strategies to mitigate risk of pulmonary aspiration.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Ozempic Vs. NPO: Postpone Or Not Postpone? (Exhibit Hall) - Aug 6, 2024 - Abstract #ASA2024ASA_4605;
On the day of surgery, gastric ultrasound showed residual food in her stomach. The case was postponed, and her case was done 3/28 after being off Ozempic for 1 week with a clear liquid diet the day before surgery, and being NPO for 8 hours prior to surgery.
- |||||||||| Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal, FDG PET: FDG PET in a Patient on a GLP-1 Agonist/Insulin Secretagogue. (Pubmed Central) - Aug 5, 2024
Clinicians should be aware of the presence of these drugs and their potential effect on biodistribution in FDG PET. Further study is needed to best understand the effects of these medications on FDG biodistribution.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Saxenda (liraglutide 3 mg) / Novo Nordisk
Retrospective data, Journal, Real-world evidence, Adherence, Real-world: Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. (Pubmed Central) - Aug 1, 2024
This GLP-1 weight loss treatment real-world analysis, among obese individuals without diabetes, found poor 1-year persistence and adherence and low rates of switching between products. These findings will aid in assessing products cost-effectiveness, understanding obesity care management program needs, forecasting future GLP-1 use and cost trends, and negotiating GLP-1 pharmaceutical manufacturer value-based purchasing agreements.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial. (Pubmed Central) - Jul 31, 2024
P3
Participants receiving semaglutide were more likely to move to a lower KDIGO risk category (odds ratio: 1.69; 95% CI: [1.32-2.16]) and less likely to move to a higher KDIGO risk category versus placebo (odds ratio: 0.71; 95% CI: [0.59-0.86]). Once weekly semaglutide versus placebo reduced risks of kidney disease end points and improved risk categories irrespective of baseline KDIGO risk.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Review, Journal: Potential kidney protective effects of glucagon-like peptide-1 receptor agonists. (Pubmed Central) - Jul 20, 2024
It has also been reported by the sponsors of the trial that the primary end point of the trial was reduced by 24% with both CKD and CV outcomes contributing to risk reduction. In anticipation of the results of the FLOW trial being published, we review the current evidence surrounding kidney outcomes and proposed kidney protective pathways associated with GLP-1RA use.
- |||||||||| Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Review, Journal: Semaglutide and obesity: beyond the nutritional and lifestyle intervention? (Pubmed Central) - Jul 19, 2024
Data in the literature on the anti-obesity action of semaglutide are available for both routes of administration of the drug, with a prevalence of studies using the s.c. one. However, given its dosage, oral semaglutide may provide greater attractiveness and better treatment adherence, but further research is needed in this field.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE) (clinicaltrials.gov) - Jul 18, 2024
P3, N=568, Active, not recruiting,
However, given its dosage, oral semaglutide may provide greater attractiveness and better treatment adherence, but further research is needed in this field. Recruiting --> Active, not recruiting
- |||||||||| Marizev (omarigliptin) / Merck (MSD)
Trial initiation date, HEOR, Real-world evidence, Real-world: Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (clinicaltrials.gov) - Jul 17, 2024
P4, N=938, Not yet recruiting,
99% of participants, and in increased numbers in those with higher NAS and fibrosis stages.This is an encore of an abstract that will be presented for the first time at the European Association for the Study of the Liver (EASL) Congress, 5 Initiation date: Jun 2024 --> Sep 2024
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Semaglutide and NYHA Functional Class (Pubmed Central) - Jul 10, 2024
P3
Initiation date: Jun 2024 --> Sep 2024 In patients with obesity-related HFpEF, fewer semaglutide-treated than placebo-treated patients had a deterioration, and more had an improvement, in NYHA functional class at 52
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Wernicke Encephalopathy Associated With Semaglutide Use. (Pubmed Central) - Jul 8, 2024
Alcoholic Wernicke encephalopathy (WE) is also another common manifestation of neurological dysfunction; however, the prevalence of non-alcoholic WE is relatively uncommon. We discuss a 37-year-old male who presented to the ED with dysphagia, slurred speech, word-finding difficulty, and restricted extraocular movements from non-alcoholic WE in the setting of semaglutide use.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Case report: Nerve fiber regeneration in children with melanocortin 4 receptor gene mutation related obesity treated with semaglutide. (Pubmed Central) - Jul 8, 2024
Both children were treated with once weekly semaglutide for 6 months with no change in weight, and only a minor improvement in HbA1c and lipid profile. However, there was evidence of nerve regeneration with an increase in corneal nerve fiber density (CNFD) [child A (13.9%), child B (14.7%)], corneal nerve branch density (CNBD) [child A (110.2%), child B (58.7%)] and corneal nerve fiber length (CNFL) [child A (21.5%), child B (44.0%)].
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
Single-center experience of effect of GLP-1 receptor agonists in adults with cystic fibrosis (104 AB) - Jul 4, 2024 - Abstract #NACFC2024NACFC_324;
With the addition of GLP-1-RAs, all experienced weight loss and a reduction in daily insulin dose, and most had improvement in pulmonary function. GLP-1-RA tolerability was similar to that reported in people without CF with diabetes or obesity treated with these agents.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open, Trial initiation date, Real-world evidence, Real-world: Special Use - Results Surveillance on Long-term Use With Wegovy (clinicaltrials.gov) - Jul 3, 2024
P=N/A, N=1000, Enrolling by invitation,
Recruiting --> Active, not recruiting Not yet recruiting --> Enrolling by invitation | Initiation date: Feb 2024 --> Jun 2024
- |||||||||| Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
PK/PD data, Review, Journal: Clinical Pharmacokinetics of Semaglutide: A Systematic Review. (Pubmed Central) - Jul 2, 2024
Food and various dosing conditions including water volume and dosing schedules can affect the oral semaglutide exposure...The existing pharmacokinetic data can assist in developing and evaluating pharmacokinetic models of semaglutide and will help clinicians predict semaglutide dosages. In addition, it can also help optimize future clinical trials.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Saxenda (liraglutide 3 mg) / Novo Nordisk
Journal: Time to unshackle the medical treatment of obesity in the NHS. (Pubmed Central) - Jun 27, 2024
In addition, it can also help optimize future clinical trials. The glucagon-like peptide-1 (GLP-1) receptor analogues, such as once-daily subcutaneous Liraglutide 3.0 mg (Saxenda
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Did the Preop Clinic Stop the Ozempic in Time? (126A) - Jun 25, 2024 - Abstract #ASA2024ASA_3046;
Are there current ASA recommendations? What would you recommend be included in the algorithm?
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
PBLD360. Did the Preop Clinic Stop the Ozempic in Time? (126A) - Jun 25, 2024 - Abstract #ASA2024ASA_3045;
What would you recommend be included in the algorithm? DESCRIPTION This Problem-Based Learning Discussion (PBLD) aims to delve into the multifaceted challenges encountered in the field of anesthesiology and offers an engaging platform for participants to deepen their understanding of anesthesiology challenges, share clinical experiences, and collaborate towards improving patient care outcomes.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Did the Preop Clinic Stop the Ozempic in Time? (126A) - Jun 25, 2024 - Abstract #ASA2024ASA_1219;
Are there current ASA recommendations? What would you recommend be included in the algorithm?
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
PBLD207. Did the Preop Clinic Stop the Ozempic in Time? (126A) - Jun 25, 2024 - Abstract #ASA2024ASA_1218;
What would you recommend be included in the algorithm? DESCRIPTION This Problem-Based Learning Discussion (PBLD) aims to delve into the multifaceted challenges encountered in the field of anesthesiology and offers an engaging platform for participants to deepen their understanding of anesthesiology challenges, share clinical experiences, and collaborate towards improving patient care outcomes.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Anesthesia and GLP-1 Agonists: A retrospective chart review (Exhibit Hall) - Jun 25, 2024 - Abstract #ASA2024ASA_597;
To power the Chi-squared tests, a significance level of ?=0.01, power of 0.95 and a small effect size of 0.05, the calculated sample size was n=26486In conclusion, we found that pneumonitis, aspiration, and ARDS were not significantly associated with GLP-1 agonists, when controlling for age, sex, race, BMI, and comorbidities categorized by the Elixhauser Comorbidity Index (Tables 3-5). There was no significant association between types of GLP-1 agonists (liraglutide vs semaglutide) and pneumonitis, when controlling for age, sex, race, BMI, and comorbidities (Table 6).
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion date, Trial primary completion date: Latino Semaglutide Study (clinicaltrials.gov) - Jun 17, 2024
P3, N=100, Recruiting,
There was no significant association between types of GLP-1 agonists (liraglutide vs semaglutide) and pneumonitis, when controlling for age, sex, race, BMI, and comorbidities (Table 6). Trial completion date: May 2024 --> Aug 2024 | Trial primary completion date: May 2024 --> Aug 2024
|
